Changes toward intended and reported adherence to monthly SSEs and changes in the absolute and relative intended frequency of SSEs immediately after genetic test reporting and at the 1-mo follow-up in each group and as a function of baseline screening status
| . | Carriers . | . | . | . | . | . | Noncarriers . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | CDKN2A/p16+ no melanoma history . | . | . | CDKN2A/p16+ melanoma history . | . | . | CDKN2A/p16− no melanoma history . | . | . | |||||||||
| . | Baseline . | Postcounseling . | 1 mo . | Baseline . | Postcounseling . | 1 mo . | Baseline . | Postcounseling . | 1 mo . | |||||||||
| Change toward adherence to monthly SSEs* | +0.78† | +1.70‡ | −0.04 | −0.45§ | +0.20 | +0.15 | ||||||||||||
| Intended and reported number of SSEs per month | ||||||||||||||||||
| Underscreeners∥ | 0.22 | 1.11† | 2.25‡ | 0.27 | 0.79 | 0.50 | 0.43 | 0.53 | 0.75 | |||||||||
| Overscreeners¶,** | 15.12 | 2.25† | 6.25 | 4.10 | 2.74 | 7.20 | 11.87 | 2.47§ | 2.00 | |||||||||
| On-target screeners†† | — | — | — | 1.00 | 1.50 | 1.63 | 1.00 | 1.00 | 2.00 | |||||||||
| Intended SSEs in future relative to current practice‡‡ | ||||||||||||||||||
| Underscreeners | 4.78‡ | 3.75§ | 3.82† | |||||||||||||||
| Overscreeners | 3.60 | 3.43 | 3.20 | |||||||||||||||
| On-target screeners | — | 3.33 | 3.25 | |||||||||||||||
| Total sample | 4.36‡ | 3.47† | 3.63‡ | |||||||||||||||
| Total sample | ||||||||||||||||||
| Baseline | Postcounseling | 1 mo | ||||||||||||||||
| Change toward adherence to monthly SSEs | +0.26§ | +0.38 | ||||||||||||||||
| Intended and reported number of SSEs per month | ||||||||||||||||||
| Underscreeners | 0.34 | 0.74§ | 1.18† | |||||||||||||||
| Overscreeners | 9.29 | 2.53† | 5.58 | |||||||||||||||
| On-target screeners | 1.00 | 1.30 | 1.79 | |||||||||||||||
| Intended SSEs in future relative to current practice | ||||||||||||||||||
| Underscreeners | 4.10‡ | |||||||||||||||||
| Overscreeners | 3.42 | |||||||||||||||||
| On-target screeners | 3.30§ | |||||||||||||||||
| Total sample | 3.76‡ | |||||||||||||||||
| . | Carriers . | . | . | . | . | . | Noncarriers . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | CDKN2A/p16+ no melanoma history . | . | . | CDKN2A/p16+ melanoma history . | . | . | CDKN2A/p16− no melanoma history . | . | . | |||||||||
| . | Baseline . | Postcounseling . | 1 mo . | Baseline . | Postcounseling . | 1 mo . | Baseline . | Postcounseling . | 1 mo . | |||||||||
| Change toward adherence to monthly SSEs* | +0.78† | +1.70‡ | −0.04 | −0.45§ | +0.20 | +0.15 | ||||||||||||
| Intended and reported number of SSEs per month | ||||||||||||||||||
| Underscreeners∥ | 0.22 | 1.11† | 2.25‡ | 0.27 | 0.79 | 0.50 | 0.43 | 0.53 | 0.75 | |||||||||
| Overscreeners¶,** | 15.12 | 2.25† | 6.25 | 4.10 | 2.74 | 7.20 | 11.87 | 2.47§ | 2.00 | |||||||||
| On-target screeners†† | — | — | — | 1.00 | 1.50 | 1.63 | 1.00 | 1.00 | 2.00 | |||||||||
| Intended SSEs in future relative to current practice‡‡ | ||||||||||||||||||
| Underscreeners | 4.78‡ | 3.75§ | 3.82† | |||||||||||||||
| Overscreeners | 3.60 | 3.43 | 3.20 | |||||||||||||||
| On-target screeners | — | 3.33 | 3.25 | |||||||||||||||
| Total sample | 4.36‡ | 3.47† | 3.63‡ | |||||||||||||||
| Total sample | ||||||||||||||||||
| Baseline | Postcounseling | 1 mo | ||||||||||||||||
| Change toward adherence to monthly SSEs | +0.26§ | +0.38 | ||||||||||||||||
| Intended and reported number of SSEs per month | ||||||||||||||||||
| Underscreeners | 0.34 | 0.74§ | 1.18† | |||||||||||||||
| Overscreeners | 9.29 | 2.53† | 5.58 | |||||||||||||||
| On-target screeners | 1.00 | 1.30 | 1.79 | |||||||||||||||
| Intended SSEs in future relative to current practice | ||||||||||||||||||
| Underscreeners | 4.10‡ | |||||||||||||||||
| Overscreeners | 3.42 | |||||||||||||||||
| On-target screeners | 3.30§ | |||||||||||||||||
| Total sample | 3.76‡ | |||||||||||||||||
NOTE: Values in boldface indicate significant changes from baseline.
Positive values indicate change in either direction toward adherence to the recommendation of 1 SSE/mo; negative values indicate a change in either direction away from the recommendation of 1 SSE/mo. Values in boldface are significantly different from 0 (no change).
P < 0.01.
P < 0.001.
P < 0.05.
Of the 30 underscreeners at baseline, 1-mo follow-up data were available for 6 of 9 participants in the CDKN2A/p16+ no melanoma history group, 2 of 4 participants in the CDKN2A/p16+ melanoma history group, and 13 of 17 participants in the CDKN2A/p16− group.
Of the 18 overscreeners at baseline, 1-mo follow-up data were available for 4 of 5 participants in the CDKN2A/p16+ no melanoma history group, 5 of 8 participants in the CDKN2A/p16+ melanoma history group, and 3 of 5 in the CDKN2A/p16− group.
These results are likely to underestimate overscreening intentions immediately following test reporting. It is important to note that the highest score participants could receive at the postcounseling assessment was 4 SSEs/mo (intentions to practice SSEs once a week or more frequently). However, the results reported for significant decreases from baseline in intentions to practice SSEs remained the same when an analogous baseline SSE measure based on verbal descriptors was used to evaluate changes from baseline in postcounseling SSE intentions.
Of the 10 on-target screeners at baseline, 1-mo follow-up data were available for 4 of 6 participants in the CDKN2A/p16+ melanoma history group and 3 of 4 participants in the CDKN2A/p16− group.
1, much less than I have been doing; 5, much more than I have been doing. Boldfaced values indicate that the group mean was significantly >3.0 (“about the same as I have been doing”) and thus represents a significant intention to increase SSEs relative to current practice.